CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated ...

Knowledge in immunology has been advanced by recent research. A new paper presents significant new findings about the protein properdin -- an important part of the immune system. It is a positive ...

Two functions have been assigned to properdin; stabilization of the alternative convertase, C3bBb, is well accepted, whereas the role of properdin as pattern recognition molecule is controversial. The ...

CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...

Novelmed Therapeutics Inc. has reported topline results with its lead anti-properdin antibody NM-3086 in a rabbit model of paroxysmal nocturnal hemoglobinuria (PNH). NM-3086 is a potent, ...

NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...

After seven years of intense research, a research group from Aarhus University has succeeded - through an interdisciplinary collaboration - in understanding why a very extended structure is important ...

A research group has succeeded in understanding why a very extended structure is important for an essential protein from the human immune system. The new results offer new opportunities for adjusting ...

A University of Leicester researcher has discovered how a protein in the blood – linked to defence against meningitis - plays a more vital role than previously understood in the body’s immune defence ...

We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen environmental ...